(Adnkronos) – Paolo Gisondi, professore associato di dermatologia dell’azienda ospedaliera universitaria integrata di Verona, spiega le caratteristiche di bimekizumab. Si tratta dell’anticorpo monoclonale per il trattamento della psoriasi che l’Aifa ha ammesso alla rimborsabilità.
Privacy Overview
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.